Weekly Dose #50 - Pause on vaccine trial; Benefits for steroid therapy in COVID patients; Higher doses of diabetes treatment okay'd; First non-hormonal contraceptive; FDA issue SCS warning episode artwork

EPISODE · Sep 11, 2020 · 11 MIN

Weekly Dose #50 - Pause on vaccine trial; Benefits for steroid therapy in COVID patients; Higher doses of diabetes treatment okay'd; First non-hormonal contraceptive; FDA issue SCS warning

from MPR Weekly Dose

We cover AstraZeneca's decision to pause their COVID-19 vaccine trial; New studies indicate benefits for steroid therapy in COVID patients; Higher doses of diabetes treatment gain approval; The first non-hormonal contraceptive is launched; The FDA issues a letter regarding spinal cord stimulators; And we  wrap up the latest news on drugs in the pipeline.

Episode metadata supplied by the publisher feed · Published Sep 11, 2020

Embed this episode

Ready to play

Weekly Dose #50 - Pause on vaccine trial; Benefits for steroid therapy in COVID patients; Higher doses of diabetes treatment okay'd; First non-hormonal contraceptive; FDA issue SCS warning

0:00 11:24

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 11 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on September 11, 2020.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!